DA-2811-C
Phase 2Small molecule
DA-2811-C is one of 24 small molecule programs targeting Type 2 Diabetes. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Lovaza
AstraZenecaPreclinical
DA-2811-C
DDong-A ST Co., Ltd.
Phase 2
Acipimox
Boehringer IngelheimPreclinical
Blank Control
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Preclinical
Routine Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DA-2811-C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDong-A ST Co., Ltd.